Related Experiment Video
Updated: May 11, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Recombinant hormones in osteoporosis.
1Aarhus University, Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark. rejnmark@post6.tele.dk
Recombinant human parathyroid hormone (rhPTH) therapy offers bone anabolic benefits for osteoporosis, reversing bone loss. However, it is not superior to anti-resorptive agents and is best reserved for severe spinal osteoporosis cases.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Bone anabolic therapy using recombinant human parathyroid hormone (rhPTH) analogues like teriparatide (rhPTH[1-34]) and full-length rhPTH(1-84) has been available for osteoporosis treatment for a decade.
- These rhPTH therapies are administered via daily subcutaneous injections, with teriparatide being the marketed form in the USA.
Purpose of the Study:
- To review the anti-fracture efficacy of rhPTH therapies based on randomized controlled trials.
- To compare the treatment effects of rhPTH with those of anti-resorptive agents.
- To explore recent findings on alternative administration schedules for rhPTH, such as less than once-daily or intermittent/cyclic therapy.
Main Methods:
- Review of randomized controlled trials evaluating the anti-fracture efficacy of rhPTH.
- Analysis of studies investigating novel administration regimens (less than once-daily, intermittent/cyclic therapy).
- Comparative analysis of rhPTH treatment effects against established anti-resorptive agents.
Main Results:
- rhPTH demonstrates bone anabolic effects by altering bone remodeling, geometry, and mineral density.
- Anti-fracture efficacy of rhPTH is comparable to potent anti-resorptive agents.
- Recent studies explore alternative rhPTH administration schedules.
Conclusions:
- While rhPTH reverses osteoporosis progression, its anti-fracture efficacy is not superior to anti-resorptive agents.
- The high cost of rhPTH limits its use compared to anti-resorptives.
- rhPTH is recommended for severe spinal osteoporosis, particularly in patients unresponsive to anti-resorptive therapy.
Related Concept Videos
Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...